Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M

Pelthos Therapeutics Inc.

2025-Q3 EPS reported -$14.96 vs consensus -$0.44 ▼ miss (-3310.9%)

Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).
2,716 units prescribed by 1,169 unique prescribers; October alone saw 2,189 units prescribed.
Net loss of $16.2M ($5.30 per basic/diluted share); as-converted net loss of $1.83/share.
Cash of $14.2M at Sep 30, 2025; closed $18M convertible notes financing in Nov 2025.
Completed acquisition of XEPI (FDA-approved impetigo treatment) in Nov 2025, adding complementary dermatology product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.